Case filing & court posture: 23andMe Holding Co. and its debtor affiliates filed for chapter 11 protection on March 23, 2025 in the U.S. Bankruptcy Court for the Eastern District of Missouri (Case No. 25-40976). Dkt. 1 The case is jointly administered under the lead debtor 23andMe Holding Co.
Liquidity & financing path: The debtors obtained a $35 million DIP facility from JMB Capital Partners Lending, LLC, which was later amended to $60 million to support operations through the sale process. Dkt. 32 The DIP facility was fully repaid upon closing of the Chrome Sale in July 2025.
Restructuring outcome: The debtors pursued a dual-track sale process for the genetic testing business and Lemonaid telehealth platform. The core genetic testing assets were sold to TTAM Research Institute (Chrome Sale) for $302.5 million, closing on July 14, 2025. Dkt. 32 The Lemonaid business was sold to Bambumeta Ventures for $10 million.
Plan effective date & post-confirmation: The Modified Fifth Amended Joint Plan of Chrome Holding Co. was confirmed on December 5, 2025, with an effective date of December 5, 2025. Dkt. 1696 The Plan established a Plan Administration Trust to handle claims resolution and distribution.
Current status: The Court entered an order closing the chapter 11 cases on January 21, 2026, with the Plan Administration Trust continuing to administer remaining claims and wind down the estates. Dkt. 1843